APEIRON Biologics AG

Campus-Vienna-Biocenter 5
Vienna,  1030 
Austria
http://www.apeiron-biologics.com
  • Booth: 19153

APEIRON Biologics AG, Vienna, Austria, engaged in immuno-oncology APN311 (ch14.18/CHO): anti-GD2 antibody for treatment of neuroblastoma. Positive opinion for marketing approval received in March by the CHMP APN301: anti-GD2 antibody-IL2 fusion protein in Phase I/II APN401: novel individual cellular cancer immunotherapy; ex-vivo silencing the checkpoint cbl-b in immune cells and re-administration. Phase I study completed APN411: low molecular weight drugs for checkpoint blockade, preclinical stage (pursued with Evotec and Sanofi) APN01 (rec. ACE2): licensed to GSK in 2010; Phase II in ARDS and PAH


  •  
  •      
     

  •  
  •